Glonghui, April 29 | Goldman Sachs released a report stating that Merck's performance is strong. In particular, the anti-cancer drug Keytruda grew 20% year over year, which is about 4% higher than the bank and market expectations. The overall execution capacity in the vaccine business is also excellent, and the company's stock price is relatively outperforming the market. The market is watching the news that the new drug Winrevair is on the market. The bank believes that Merck's pharmaceutical channel opportunities continue to increase, especially at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. Although it is not expected that the company will disclose significant data, it can better understand its strategic initiatives. The bank raised Merck's target price from $139 to $144, reaffirming the “buy” rating.
大行评级｜高盛：上调默克目标价至144美元 评级“买入”
Major Bank Ratings | Goldman Sachs: Raising Merck's Target Price to $144, Rating “Buy”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.